UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors
  • 1200x675.UCB_LOGO_TAG_C_RGB_600.jpg

    Sep

    22

    UCB Achieves Important Regulatory Milestone for Bimekizumab

    • The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have accepted marketing application submissions for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis
    • This accepted submission is supported by a robust data package including three Phase 3 studies which demonstrate superiority of bimekizumab to placebo, Stelara® (ustekinumab) and Humira® (adalimumab) in achieving skin clearance at week 16
    1200x675.UCB_LOGO_TAG_C_RGB_600.jpg

    Sep

    14

    Final Phase II Results for UCB’s Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) Published in Blood Advances

    •    Phase II data demonstrated a favorable safety profile across all reported dose groups and clinically meaningful platelet count increases with meaningful decreases in IgG concentration